Purchase this article with an account.
Rym Ben Abdelwahed, Sabrina Donnou, Hanane Ouakrim, Lucile Crozet, Jérémie Cosette, Alexandra Jacquet, Isabel Tourais, Bénédicte Fournès, Mélanie Gillard Bocquet, Amine Miloudi, Valérie Touitou, Cécile Daussy, Marie-Christine Naud, Wolf Herman Fridman, Catherine Sautès-Fridman, Rémi Urbain, Sylvain Fisson; Preclinical Study of Ublituximab, a Glycoengineered Anti-Human CD20 Antibody, in Murine Models of Primary Cerebral and Intraocular B-Cell Lymphomas. Invest. Ophthalmol. Vis. Sci. 2013;54(5):3657-3665. doi: https://doi.org/10.1167/iovs.12-10316.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Primary cerebral lymphoma (PCL) and primary intraocular lymphoma (PIOL) belong to the systemic diffuse large B-cell lymphoma family and are characterized by the presence of CD20+ lymphoma B cells in the brain or the eye. These highly aggressive malignancies have a poor prognosis and no specific therapy. The presence of effector immune cells in the damaged brain and vitreous suggests that treatment with anti-human CD20 (hCD20) monoclonal antibodies might be effective. We developed murine models of PCL and PIOL to assess the intracerebral and intraocular antitumor effect of ublituximab, a promising glycoengineered anti-hCD20 mAb with a high affinity for FcγRIIIa (CD16) receptors.
The murine lymphoma B-cell line A20.IIA-GFP-hCD20 (H-2d) was injected into the right cerebral striatum or the vitreous of immunocompetent adult BALB/c mice (H-2d). Four to 7 days later, ublituximab was injected intracerebrally or intravitreously into the tumor site. Rituximab was the reference compound. Survival was monitored for injected mice; histopathological and flow cytometric analyses were performed to study tumor growth and T-cell infiltration.
Single doses of ublituximab, injected intracerebrally or intravitreously, had a marked antitumor effect, more pronounced than that obtained with the same dose of rituximab in these conditions. The reduction in tumor cells was correlated with an increased proportion of CD8+ T cells. This efficacy was observed only against lymphoma B cells expressing hCD20.
These in vivo results confirm the potential of the glycoengineered anti-hCD20 mAb ublituximab as an innovative therapeutic approach to treat primary central nervous system lymphoma and other B-cell lymphomas.
This PDF is available to Subscribers Only